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Abstract 
Pancreatic cancer has become the 3rd leading cause of cancer death, with little 
improvement in outcomes despite decades of research. Surgery remains the only 
chance of cure, yet, only 20% will be alive at 5 years after pancreatic resection. Few 
chemotherapeutics provide any improvement in outcome, and even then, for approved 
therapies, the survival benefits are marginal. Genomic sequencing studies of 
pancreatic cancer have revealed a small set of consistent mutations found in most 
pancreatic cancers, and beyond that a low prevalence for targetable mutations. This 
may explain the failure of conventional clinical trial designs to show any meaningful 
survival benefit, except in small and undefined patient sub-groups. With the 
development of next generation sequencing technology, genomic sequencing and 
analysis can be performed in a clinically meaningful turnaround time. This can identify 
therapeutic targets in individual patients and personalize treatment selection. 
Incorporating pre-clinical discovery and molecularly guided therapy into clinical trial 
design has the potential to significantly improve outcomes in this lethal malignancy. In 
this review, we discuss the findings of recent large scale genomic sequencing projects 
in pancreatic cancer and the potential relevance of these data to therapeutic 
development. 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) has become the 3rd leading cause of 
cancer related death in Western societies, recently overtaking breast cancer (1). The 
5-year survival, almost unchanged in 50 years, remains less than 10%(1). Surgical 
resection is the only chance of cure with chemotherapy adding only modest benefit(2, 
3). Apart from a few exceptions, most clinical trials in PDAC have failed to demonstrate 
a clinically meaningful survival benefit. This is perhaps not surprising as recent 
genomic sequencing studies revealed that apart from a few well-known mutations in 
KRAS, TP53, CDKN2A and SMAD4, and a few at around 10% prevalence (e.g.: 
KDM6A, RBM10, MLL3), most occur at a rate of less than 5% (Figure 1)(4, 5). The 
proto-oncogene, KRAS, is mutated in almost 95% of PDAC, yet no therapeutic has 
been shown to successfully target mutant KRAS. This is currently a major area of 
research interest, resulting in the National Cancer Institute launching the RAS initiative 
to explore therapeutics for targeting RAS proteins(6). Currently, there are no 
therapeutics that target driver mutations in PDAC of >20% prevalence. This hampers 
clinical trial efficiency as the responsive phenotype of a therapeutic regimen would fall 
below the detection threshold of a conventional randomized-controlled trial design. 
Consequently, there is an urgent need to develop novel therapeutic approaches that 
leverage treatment selection for patients with PDAC.  
 
Somatic driver events 
The inter-tumor heterogeneity of PDAC was first revealed after capillary based exome 
sequencing and SNP microarrays demonstrated that the genetic landscape of PDAC 
consists of a small number of frequently mutated genes, followed by a long tail of 
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infrequent mutations(5). These segregate into 12 core signaling pathways that 
contribute to the hallmarks of cancer, including KRAS signaling, DNA damage control, 
WNT/Notch signaling and TGF- signaling(5, 7).  
The Australian Pancreatic Cancer Genome Initiative (APGI), as part of The 
International Cancer Genome Consortium (ICGC), comprehensively analyzed the 
genomic, transcriptomic and epigenetic aberrations that characterize PDAC and 
increased our understanding of the underlying molecular pathology of PDAC. Whole 
exome sequencing and copy number analysis of 99 resected PDACs, confirmed the 
presence of known frequently mutated genes (KRAS, TP53, CDKN2A, SMAD4, MLL3, 
TGFBR2, ARID1A and SF3B1), and revealed mutations in DNA damage repair (ATM), 
chromatin modification (EPC1 and ARID2) and axon guidance in SLIT/ROBO 
signaling(4). A similar study used exome sequencing and revealed the BRAF mutation 
V600E is present in 3% of patients, and exclusively in KRAS wild-type PDAC(8). This 
sub-group of tumors can potentially be targeted using the BRAF inhibitor Vemurafinib, 
and warrants further investigation(8).  
Whole genome sequencing (WGS) and copy number alterations go beyond point 
mutations in genes and measure alterations in DNA structure such as insertions, 
deletions, translocations and amplifications. These analyses revealed distinct 
chromosomal instability patterns, processes that underlie somatic mutagenesis and 
novel driver mutations (KDM6A and PREX2) not previously described in PDAC(9). 
KDM6A, a SWI/SNF interacting partner involved in demethylation of lysine residues 
on histone, was found in 18% of patients, and is associated with a poor prognostic 
sub-type of PDAC(10). Inactivating mutations in the tumor suppressor gene RNF43 
occurred in 10% (2 cases due to structural variants) and may offer therapeutic 
opportunities for WNT signaling antagonists in selected patients(11). Importantly, 
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whole genome and copy number analyses demonstrated novel putative read-outs of 
DNA damage response (DDR) deficiency, identifying a greater proportion of patients 
with DDR deficiency in PDAC than that based on mutations in individual DNA 
maintenance genes alone(9). 
Resected PDAC that underwent WGS demonstrated 4 sub-types based on the 
number and pattern of chromosomal structural variants (Figure 1) (9). Waddell et al. 
classified tumors as stable (≤50 structural variations; 20% of all samples), locally 
rearranged (a significant focal event on 1 or 2 chromosomes; 30% of all samples), 
scattered (moderate range of chromosomal damage, <200 structural variations; 36% 
of all samples) and unstable (> 200 structural variations; 14% of all samples). The 
scale of genomic instability in the unstable sub-type (up to 558 structural variations) 
suggests significant defects in DNA maintenance, particularly in the homologous 
recombination (HR) pathway (9, 12). 
Somatic point mutational signatures (COSMIC signatures) within a cancer genome 
reflect the underlying processes contributing to mutagenesis, and to date, 4 with 
known etiology have been associated with PDAC (BRCA mutational signature, Old 
Age, DNA mismatch repair deficiency, and the APOBEC family of cytidine 
deaminases) (Figure 1) (13, 14). WGS analysis demonstrated that 10 of the 14 
patients with unstable genomes were within the top quintile of BRCA mutational 
signature prevalence (Figure 2) (9). Germline BRCA mutations accounted for only 4% 
of patients, and adding germline PALB2 mutations increases this to 7%(9). Including 
somatic mutations in BRCA 1, BRCA 2, PALB2 captures double that number to 14% 
of patients, all of which were associated with an unstable genome or a BRCA 
mutational signature(9). However, an unstable genome or BRCA mutational signature 
were present in 24% of patients, yet, potential causative genes are challenging to 
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define and have only been detected as single events to date (e.g. ATM, RPA1, XRCC4 
and XRCC6). These findings indicate that DDR deficiency occurs in up to 24% of 
PDACs and there exists significant overlap between unstable genomes, high ranking 
BRCA mutational signature and mutations in key DDR genes (Figure 2)(9). 
Suggesting that more than germline pathogenic variants and somatic point mutations 
may be important in patient selection for clinical trials of agents targeting DDR 
deficiency(9).  
More recently, a novel informatics tool assessed ploidy, copy number changes and 
chromothripsis (a single event that leads to thousands of chromosomal 
rearrangements, usually confined to one or few chromosomes) in PDAC, challenging 
the model of stepwise progression from PanIN to invasive PDAC(15). Approximately 
65% of tumors demonstrated evidence of at least one chromothriptic event, and most 
copy number changes appear to occur after such catastrophic genetic events(15). By 
analyzing the genomes of two PDAC tumors in detail, the authors demonstrated 
evidence of chromothripsis leading to loss of tumor suppressors CDKN2A, TP53 and 
SMAD4 (15). This suggests a proportion of PDAC tumors may not follow the stepwise 
progression model and could explain the rapid clinical progression of the disease in 
some patients. Chromothripsis leads to significant genetic instability and subsequently 
worse clinical outcomes for patients whose tumors had at least one such event(15). 
 
Transcriptome  
An integrated molecular analysis of ICGC PDAC donors identified 4 sub-types based 
on transcriptional networks that define gene programs within the tumor epithelial 
component and the microenvironment(10). Sub-types were named squamous, 
pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine 
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(ADEX) and correlated with histopathological subtypes of PDAC and survival (Figure 
2)(10).  
The squamous sub-type is so-called as it is enriched for gene programs described in 
squamous like tumors of breast, bladder, lung and head and neck cancer(16). These 
co-segregate with histopathological adeno-squamous tumors and gene programs 
associated with inflammation, hypoxia response, metabolic programming and TGF- 
signaling(10). MYC pathway activation was enriched in this sub-type, and correlates 
with a previous study demonstrating MYC activation in adeno-squamous tumors and 
poor outcome(8, 10). Hypermethylation and downregulation of genes involved in 
pancreatic endodermal differentiation (PDX1, MNX1, GATA6, HNF1B) appear to 
contribute to loss of endodermal identity and epithelial to mesenchymal transition 
(EMT) (10). Mutations in KDM6A and TP53 associate with other squamous epithelial 
tumors, and this class was associated with poor survival in PDAC with EMT(7, 17, 18). 
In contrast with the squamous sub-type, the pancreatic progenitor sub-type is 
associated with better survival and is primarily defined by pathways and networks 
involved in pancreatic endodermal differentiation(10). The progenitor class 
demonstrated increased expression of the apomucins MUC1 and MUC5AC, both 
associated with the pancreatico-biliary subtype of intra-ductal papillary mucinous 
neoplasms (IPMN) and with invasive IPMN cancer histologically (Figure 2) (10).  
Within the progenitor class, perhaps the most exciting finding was a third subtype—
the so-called immunogenic sub-type, which was defined by enrichment for pathways 
involved in immune cell infiltration and associated immune signaling pathways(10). 
Evidence of infiltrating cytotoxic CD8+ T cells, regulatory T and B cells along with 
expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed 
cell death 1 (PD-1) immune checkpoint pathways suggests immune suppression that 
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can be targeted with checkpoint blockade in this class(10). Expression signatures of 
immune cells predicted outcome, specifically macrophage infiltration and T cell co-
inhibition associated with poor survival(10). This provides rationale for using 
transcriptome analysis for identifying patients that will respond to immunotherapy in 
PDAC. 
The fourth subtype described by Bailey et al. was the ADEX class. In a separate 
analysis, Collisson et al. categorized PDAC, using transcriptional analysis, into quasi-
mesenchymal (QM-PDA), classical and exocrine subtypes(19). The QM-PDA sub-
group was associated with worse overall survival and overlaps with the squamous 
sub-type described by Bailey et al.(10, 19). Collisson further described an exocrine 
sub-type that overlaps directly with the Bailey ADEX class (Figure 2)(10, 19). These 
were enriched for gene programs in endocrine and exocrine development and appears 
to be a sub-group of the progenitor class (10, 19). 
Moffitt et al. performed virtual microdissection to differentiate the stromal and epithelial 
components of PDAC, and minimize the confounding impact normal pancreatic tissue 
may confer(20). They described two sets of gene programs that define either an 
activated or normal stroma(20). The activated stroma was associated with a worse 
prognosis and enriched for genes previously associated with poor survival including 
MMP9, MMP11 and Wnt family members(20). Defining gene expression within the 
epithelial component revealed 2 sub-types, named basal and classical(20). The 
classical sub-type was associated with improved prognosis and overlapped with the 
Collisson classical and Bailey progenitor sub-types (Figure 2)(10, 19, 20).  
Comparing Moffit’s basal sub-type with the QM-PDA sub-type, described by Collisson 
et al., revealed that the QM-PDA classification considers gene programs from the 
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basal epithelial and activated stroma classes(19, 20).  Further study is required to 
shed further light on the biology and the clinical relevance of these classifications. 
 
Inherited PDAC 
Up to 10% of PDAC cases are due to inherited susceptibility, and 20% of these form 
part of well-known cancer syndromes such as Familial Adenomatous Polyposis (FAP), 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC), Familial Multiple Mole 
Melanoma (FaMMM), Li Fraumeni syndrome, Hereditary Breast and Ovarian Cancer 
(HBOC) syndrome, or Peutz-Jegher syndrome(21).  Hereditary pancreatitis appears 
to increase the risk of PDAC, particularly in the setting of PRSS1, SPINK1 and 
potentially CPA1 mutations(21, 22). Roberts et al. sequenced the genomes of 638 
patients with familial pancreatic cancer (FPC) and reaffirmed known PDAC 
susceptibility genes such as ATM, BRCA2, CDKN2A and PALB2, but also revealed 
rare germline variants that likely play a role in the disease(22, 23). Importantly, several 
novel FPC susceptibility genes were identified and are involved in DNA damage repair 
or chromosomal stability processes. Newly identified mutations in BUB1B, CPA1, 
FANCC and FANCG may thus predispose these patients to sensitivity for 
chemotherapeutics targeting the DNA damage repair pathway(22). This study 
illustrated the challenges in identifying and defining low prevalence PDAC 
susceptibility mutations and further work to delineate these associations and their 
therapeutic implications is encouraged.  
 
Intra-tumoral Heterogeneity in Pancreatic Cancer 
There is growing evidence that individual tumors are composed of multiple clonal sub-
sets with differing mutations resulting in various levels of intra-tumoral heterogeneity 
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(ITH) (24-31). Comparative sequencing of multiple PDAC lesions suggested that most 
somatic mutations occur in the primary tumor (founder mutations) prior to metastatic 
dissemination, and ‘progressor’ mutations occur during further clonal evolution(32). 
Multiple, three-dimensionally spaced samples sequenced from primary tumors 
suggest multiple sub-clones within the primary tumor, which results in metastases 
originating from specific primary tumor sub-clones and thus ITH selects for metastatic 
sub-clones (32). However, it seems that phylogenetic relationships between primary 
tumors and metastases are distant suggesting that metastatic clones undergo 
significant evolution to obtain the survival advantage required for disease 
dissemination(20, 33).  
The findings from these studies suggest that PDAC harbors significant ITH, 
particularly amongst the primary tumor and metastatic lesions but ITH patterns differ 
significantly from other tumor types(24, 26, 32-35). Yet, the extent of ITH in driver 
mutations and clonal evolution of PDAC before and during treatment is far from fully 
defined.  The significance of ITH in PDAC and its implications on therapeutic and 
molecular characterization strategies to deliver precision medicine still require 
extensive investigation, particularly as recent data concerning multiple metastases in 
untreated patients show little variability of driver events(36). 
 
Molecular targets in PDAC 
A deeper understanding of the molecular pathology of PDAC has led to the 
identification of multiple therapeutic targets in the disease, as is discussed by 
Borazanci et al. and Manji et al. elsewhere in this CCR focus section(37, 38) (Figure 
2).Most actionable targets occur at low prevalence in PDAC, and therefore 
molecularly-guided, personalized treatment approaches can allow selection and 
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repurposing of therapies used successfully in other cancers. The low prevalence of 
these targets perhaps explains why studies of targeted therapies in unselected PDAC 
participants have not been successful. However, several opportunities, supported by 
our increased appreciation of the molecular pathology of PDAC are emerging. 
 
Targeting DDR deficiency 
Accumulating case reports and evidence from exceptional responders are identifying 
candidate molecular targets for current and novel therapeutics in PDAC(39). Perhaps 
the most promising, at present, is targeting DNA damage response (DDR) deficiency. 
Up to 24% of PDAC demonstrate defects in DDR and can potentially be targeted with 
DNA damaging agents or DDR targeted agents through synthetic lethality and other 
mechanisms (9, 40). Integrated genomic readouts of DDR deficiency are emerging as 
potentially more appropriate than using simple mutations alone and can potentially 
identify patients that will respond to platinum based therapy, PARP inhibition or novel 
agents that target DDR pathways (Table 1) (9). A significant proportion of patients with 
PDAC harbor heterozygous mutations in DDR pathways with unknown functional 
consequences. The term BRCAness refers to tumors in which HR deficiency exist, 
without evidence of a germline BRCA1 or BRCA2 mutation(41). These can be defined 
in part by the Cosmic BRCA mutational signature or an unstable genome, and can be 
associated with mutations in ATM, ATR, PALB2 and potentially others such as RPA1 
(Figure 2)(9, 41). The benefit of targeting heterozygous somatic or germline mutations 
with synthetic lethality strategies is yet to be determined and are complicated by our 
lack of knowledge concerning the functional consequences of many observed 
mutations in DDR genes. In addition,  the consequence of haplosufficiency for several 
DDR genes is undefined at present and there exists no consensus on whether the loss 
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of the 2nd allele is required to predict therapeutic sensitivity for the majority of genes 
involved in DDR. 
The evidence for platinum therapy in PDAC is ever increasing in the neoadjuvant, 
adjuvant and palliative settings (42-47). Exceptional responders to platinum therapy 
are well documented, yet biomarkers of response require testing in prospective clinical 
trials(9, 39). BRCA1 and BRCA2 germline carriers are known to respond to platinums 
and PARP-inhibitors in multiple tumor types including early data for PDAC(41, 48). 
Platinum resistance, however, is common and can occur after secondary BRCA1 or 
BRCA2 mutations, or other mechanisms (49-54). 
Novel targeted DDR agents such as ATR and ATM inhibitors offer significant potential 
in early pre-clinical studies, however their role and defining patient selection markers 
requires further investigation (55-61). At present, this perhaps shows most promise in 
ATM deficient PDAC, which can occur in up to 8% of patients and is associated with 
FPC, as normal DDR mechanisms become reliant on ATR signaling following ATM 
down-regulation(60). Mutations in ATM (found in 8% of the ICGC cohort described by 
Waddell et al.) may predict sensitivity to targeted DNA damaging agents (e.g. PARP-
inhibitors or ATR inhibitors), however it remains to be determined whether ATM 
mutation, gene expression or immunohistochemistry is the ideal predictive biomarker 
for response in this patient sub-group(62). There is growing evidence that mutations 
in chromatin remodeling pathways (e.g. ARID1A mutations) can be targeted using 
PARP- or ATR-inhibitors (40, 55, 60, 62-64). These mutations are associated with the 
poor prognostic squamous sub-type and may provide a therapeutic strategy to target 
this sub-set of patients(10). 
 
Immunotherapy 
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As discussed elsewhere by in this CCR focus section, achieving significant advances 
in PDAC will likely require multi-modal therapeutic strategies to target the epithelial, 
stromal and immune components of the tumor(38, 65). Transcriptomic analyses have 
identified sub-groups of tumors with differential stromal and immune signatures. Of 
relevance, is the immunogenic sub-type that demonstrates up-regulated immune 
avoidance mechanisms such as PD-1 and CTLA-4 (10). Using transcriptomic 
readouts, immune and stromal signatures can potentially be generated in an 
acceptable time-frame which can stratify immunotherapy in PDAC. Current strategies 
for targeting PDAC with immunotherapy is discussed in detail by Johnson et al. 
elsewhere in this CCR focus section(66).  
The mutational burden in tumors with mismatch repair (MMR) deficiency is greatly 
increased in PDAC(67). Mutations in MMR genes (MSH2, MLH1) and a recently 
described MMR mutational signature(13) are associated with MMR deficiency and the 
highest burden of somatic mutations in around 1% of PDAC(67). Immune checkpoint 
inhibitors have shown great promise in melanoma, colorectal and non-small cell lung 
cancer, particularly in those tumors with hypermutation and MMR deficiency (68-70). 
Recent analysis demonstrated that MMR and BRCA mutational signatures correlate 
with antitumor immune responses in PDAC(71). To date, the results of immune 
checkpoint blockade have not been encouraging in PDAC(72). It is likely that 
increased neoantigen load contributes to antitumor cytolytic activity, a requirement for 
immunotherapy response, however the PDAC microenvironment is complex and 
further study is required to define dependencies and vulnerabilities that can be 
targeted with immunotherapy. 
Targeting immune signaling pathways can prime immune responses in non-
immunogenic tumors and enhance sensitivity to checkpoint blockade and 
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chemotherapy(73-76). Inhibition of CXCR2, focal adhesion kinase 1 and stimulation 
of CD40 leads to enhanced T-cell tumor infiltration and checkpoint blockade 
response(73, 75, 76). Inhibiting the CCR2-CCL2 axis modulates both T and non-T cell 
immune mechanisms, potentially leading to enhanced response in combination with 
cytotoxic chemotherapy(74). Intriguingly, it appears that myeloid cell depletion is 
crucial to inducing durable anti-tumor immune responses (73, 74, 77). With increasing 
immunotherapies becoming available and entering clinical trials, there is an urgent 
need to identify biomarkers of response to stratify patients to effective immunotherapy 
combinations at appropriate time-points in the tumor life-span.  
 
Future strategies 
In addition to the afore-mentioned treatment strategies, genomic sequencing has 
revealed multiple therapeutic targets in PDAC (Figure 2). Identifying exceptional 
responders and repurposing existing therapies has the potential to increase 
therapeutic options. Efficient advancement of these strategies will require platforms 
that align discovery, preclinical and clinical development and are emerging. Two such 
platforms have been established: ‘PRECISION-Panc’ in the United Kingdom and 
‘PRECISION-Promise’ in the USA are therapeutic development platforms that aim to 
deliver coordinated pre-clinical drug discovery and personalized medicine 
approaches. Patient-centric clinical trial strategies that “find the trial” for the patient 
drive a coordinated approach to discovery and prioritization of preclinical and early 
therapeutic development. Integrating drug response data and molecular analyses from 
patient biospecimens may allow the identification of novel therapeutic segments, as 
well as test existing and emerging therapeutics in individually small, but cumulatively 
large proportions of PDAC patients. One caveat is that the discovery of a particular 
 15 
“actionable” mutation does not guarantee that the particular pancreatic cancer is 
dependent on that target. Only clinical trial will determine how well this strategy will 
work.  
 
Conclusion 
Genomic analyses have improved our understanding of the complex molecular 
pathology of PDAC. Studies are revealing molecular sub-sets of patients that may 
have durable responses to specific therapies and strategies are being developed to 
test these assertions. Treatment resistance, however, remains a significant problem 
even in those that respond initially. Extensively characterized pre-clinical models are 
crucial to identify novel therapeutic targets, responsive molecular patient sub-sets and 
dissect out treatment resistance mechanisms in PDAC. Successful translation of 
large-scale genomic discoveries requires novel clinical approaches to develop and 
incorporate personalized medicine into PDAC in order to improve outcomes in this 
lethal disease. 
Figure legends 
Figure 1. Whole genome characterization of PDAC. a, Somatic mutations in the 
most commonly mutated genes in 456 samples. b, Subtypes of PDAC based on the 
number and pattern of chromosomal structural variants. The coloured outer rings are 
chromosomes, the following ring represents copy number changes (red equals gain, 
green equals loss), the following represents allele frequency, the inner lines represent 
chromosome structural re-arrangements. c, Examples of Cosmic mutational 
signatures defined by base substitutions in the human genome seen in PDAC, 
including the BRCA mutational signature. Overall, there are 6 possible types of base 
substitutions (C>A, C>G, C>T, T>A, T>C, T>G) and incorporating information on the 
bases 5' and 3' to each mutated base, along with the type of base substitution results 
in 96 possible combinations, and generates a signature of somatic mutagenesis. d, 
Mutated genes and the pathways where they occur in PDAC. 
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Figure 2. DDR deficiency, transcriptional networks and therapeutic 
opportunities in PDAC. a, Defining the DDR deficient subtype using mutations in 
genes and other measures of DDR deficiency (mutational signatures and genomic 
instability): Cosmic BRCA mutational signature (defined as BRCA signature 
mutations per MB), ranked by prevalence and relationship to unstable  genomes  and  
point mutations within BRCA pathway genes.  Taking into account germline & somatic 
mutations in well-defined DDR genes, unstable genomes and the BRCA mutational 
signature, DDR deficiency prevalence increases to 24% (green bar separates upper 
quintile of BRCA mutational signature prevalence) b, Transcriptional networks reveal 
4 PDAC sub-types: Squamous (blue), ADEX (aberrantly differentiated endocrine and 
exocrine; brown); pancreatic progenitor   (yellow), and immunogenic (red). Bailey 
subtypes aligned with Moffit tumor and stromal class, and Collisson classes.  c, 
Kaplan-Meier survival analysis of Bailey subtypes, d, PDAC actionable genome, 
based on genomic aberrations, showing therapeutic opportunities for existing and 
emerging therapies in PDAC. It is important to note that whilst these targets exist, we 
know very little concerning the functional consequences of many of these events, nor 
the potential therapeutic responsiveness to agents that target them. 
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Table 1     
Significantly mutated genes in DDR pathway in PDAC 
Gene symbol Therapeutic Rationale References Estimated 
prevalence (%) 
ARID1A ATR inhibitor / PARP inhibitor / 
Platinum 
Pre-clinical models (63, 64) 16 
ATM ATR inhibitor / PARP inhibitor / 
Platinums 
Clinical Trials / Case reports / Pre-
clinical models 
(4, 55, 59, 60, 
62, 78-81) 
10 
ATR PARP-inhibitor / ATM inhibitor Pre-clinical models (60) 1 
BRCA1 
BRCA2 
Platinums / PARP inhibitor / ATR 
inhibitor  
Clinical trials / Case reports / Pre-
clinical models 
(9, 23, 40, 41, 
82, 83) 
7 
PALB2 Platinums / PARP inhibitor Case reports / Pre-clinical models  (9, 41, 84) 2 
RAD51 
RAD51C 
PARP-inhibitors Clinical trials / Pre-clinical models (85, 86) 1 
RPA1 Platinums / PARP-inhibitor Pre-clinical models (9, 85) 3 
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signature
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a
